Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Operations (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Cash from Operations readings, the most recent being 1616006.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 52.54% to 1616006.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 5331073.0, a 57.44% increase, with the full-year FY2025 number at 5331073.0, up 57.44% from a year prior.
  • Cash from Operations hit 1616006.0 in Q4 2025 for Sunshine Biopharma, down from 727800.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 297355.0 in Q1 2021 to a low of 4577784.0 in Q2 2024.
  • Median Cash from Operations over the past 5 years was 1330392.5 (2022), compared with a mean of 1685422.45.
  • Biggest five-year swings in Cash from Operations: plummeted 858.16% in 2021 and later soared 72.18% in 2025.
  • Sunshine Biopharma's Cash from Operations stood at 312113.0 in 2021, then tumbled by 619.81% to 2246612.0 in 2022, then decreased by 19.72% to 2689676.0 in 2023, then fell by 26.6% to 3405260.0 in 2024, then soared by 52.54% to 1616006.0 in 2025.
  • The last three reported values for Cash from Operations were 1616006.0 (Q4 2025), 727800.0 (Q3 2025), and 1273432.0 (Q2 2025) per Business Quant data.